Hyperlipidemia

Episodes 33-43 of 43

• 

  MinuteCE®

  The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management

  1.00 credit 4 episodes

  • 

    

    Kausik Ray, MBChB, MD, MPhil

  • 

    

    Lale Tokgözoğlu, MD

  • 

    

    Fabrice Martens

  • 

    

    Erin Michos

  1.00 credit 4 episodes

• 

  RestartResume

  Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi 
  

  RestartResume

  Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi 
  

  MinuteCE®

  Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi 
  

  1.00 program credit

  • 

    

    Erin Michos

  1.00 program credit

• 

  RestartResume

  The evolving need and challenges to reach LDL-c targets in high-risk patients 
  

  RestartResume

  The evolving need and challenges to reach LDL-c targets in high-risk patients 
  

  MinuteCE®

  The evolving need and challenges to reach LDL-c targets in high-risk patients 
  

  1.00 program credit

  • 

    

    Kausik Ray, MBChB, MD, MPhil

  1.00 program credit

• 

  RestartResume

  Unmet needs in lowering LDL-c

  RestartResume

  Unmet needs in lowering LDL-c

  MinuteCE®

  Unmet needs in lowering LDL-c

  1.00 program credit

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  1.00 program credit

• 

  RestartResume

  Exploring the role of a novel CETP inhibitor in lipid management

  RestartResume

  Exploring the role of a novel CETP inhibitor in lipid management

  MinuteCE®

  Exploring the role of a novel CETP inhibitor in lipid management

  1.00 program credit

  • 

    

    Roxana Mehran, MD

  1.00 program credit

• 

  MinuteCE®

  Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?

  1.00 credit 3 episodes

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  • 

    

    Roxana Mehran, MD

  1.00 credit 3 episodes

• 

  RestartResume

  New insights on CETP inhibition from genetic research and clinical trials

  RestartResume

  New insights on CETP inhibition from genetic research and clinical trials

  MinuteCE®

  New insights on CETP inhibition from genetic research and clinical trials

  1.00 program credit

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  1.00 program credit

• 

  RestartResume

  Reassessing the role of triglycerides in residual cardiovascular risk

  RestartResume

  Reassessing the role of triglycerides in residual cardiovascular risk

  MinuteCE®

  Reassessing the role of triglycerides in residual cardiovascular risk

  1.00 program credit

  • 

    

    Richard Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Integrating icosapent ethyl in preventive strategies: Practical guidance

  RestartResume

  Integrating icosapent ethyl in preventive strategies: Practical guidance

  MinuteCE®

  Integrating icosapent ethyl in preventive strategies: Practical guidance

  1.00 program credit

  • 

    

    Victor Aboyans, MD, PhD

  1.00 program credit

• 

  RestartResume

  The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

  RestartResume

  The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

  MinuteCE®

  The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

  1.00 program credit

  • 

    

    Lale Tokgözoğlu, MD

  1.00 program credit

• 

  MinuteCE®

  New paradigms in the prevention of ASCVD: The role of EPA and triglycerides

  1.00 credit 3 episodes

  • 

    

    Richard Hobbs, MD

  • 

    

    Lale Tokgözoğlu, MD

  • 

    

    Victor Aboyans, MD, PhD

  1.00 credit 3 episodes